Literature DB >> 28886264

Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed-dose combination therapy in Australia.

Sinthia Bosnic-Anticevich1, Vicky Kritikos1, Victoria Carter2, Kwok Yin Yan3, Carol Armour4, Dermot Ryan5, David Price6.   

Abstract

OBJECTIVES: The first aim of the study (i) assess the current asthma status of general-practitioner-managed patients receiving regular fixed-dose combination inhaled corticosteroid and long-acting beta2 agonist (FDC ICS/LABA) therapy and (ii) explore patients' perceptions of asthma control and attitudes/behaviors regarding preventer inhaler use.
METHODS: A cross-sectional observational study of Australian adults with a current physician diagnosis of asthma receiving ≥2 prescriptions of FDC ICS/LABA therapy in the previous year, who were recruited through general practice to receive a structured in-depth asthma review between May 2012 and January 2014. Descriptive statistics and Chi-Square tests for independence were used for associations across asthma control levels.
RESULTS: Only 11.5% of the patients had controlled asthma based on guideline-defined criteria. Contrarily, 66.5% of the patients considered their asthma to be well controlled. Incidence of acute asthma exacerbations in the previous year was 26.5% and 45.6% of the patients were without a diagnosis of rhinitis. Asthma medication use and inhaler technique were sub-optimal; only 41.0% of the preventer users reported everyday use. The side effects of medication were common and more frequently reported among uncontrolled and partially controlled patients.
CONCLUSIONS: The study revealed the extent to which asthma management needs to be improved in this patient cohort and the numerous unmet needs regarding the current state of asthma care. Not only there is a need for continuous education of patients, but also education of health care practitioners to better understand the way in which patient's perceptions impact on asthma management practices, incorporating these findings into clinical decision making.

Entities:  

Keywords:  Adherence; inhaler; management; medication:preventer; primary care; side effects

Mesh:

Substances:

Year:  2017        PMID: 28886264     DOI: 10.1080/02770903.2017.1353611

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  14 in total

Review 1.  ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye.

Authors:  Ayşe Arzu Yorgancıoğlu; Bilun Gemicioğlu; Cemal Cingi; Ömer Kalaycı; Ali Fuat Kalyoncu; Claus Bachert; Peter Hellings; Oliver Pfaar; Holger J Schünemann; Dana Wallace; Anna Bedbrook; Wienczyslawa Czarlewski; Jean Bousquet
Journal:  Turk Thorac J       Date:  2020-03-01

2.  Characterisation of the Australian Adult Population Living with Asthma: Severe - Exacerbation Frequency, Long-Term OCS Use and Adverse Effects.

Authors:  Kerry L Hancock; Sinthia Bosnic-Anticevich; John D Blakey; Mark Hew; Li Ping Chung; Biljana Cvetkovski; Scott Claxton; Peter Del Fante; Eve Denton; Joe Doan; Kanchanamala Ranasinghe; Lucy Morgan; Anita Sharma; Peter K Smith; Deb Stewart; Philip J Thompson; Russell Wiseman; John W Upham; Kwok Y Yan; Victoria Carter; Kiranjeet Dhillon; Florian Heraud; Thao Le; Rebecca Vella; David Price
Journal:  Pragmat Obs Res       Date:  2022-07-05

3.  Nationwide use of inhaled corticosteroids by South Korean asthma patients: an examination of the Health Insurance Review and Service database.

Authors:  Joon Young Choi; Hyoung Kyu Yoon; Jae Ha Lee; Kwang Ha Yoo; Bo Yeon Kim; Hye Won Bae; Young Kyoon Kim; Chin Kook Rhee
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  A patient-centric analysis to identify key influences in allergic rhinitis management.

Authors:  Biljana Cvetkovski; Rachel Tan; Vicky Kritikos; Kwok Yan; Elizabeth Azzi; Pamela Srour; Sinthia Bosnic-Anticevich
Journal:  NPJ Prim Care Respir Med       Date:  2018-09-13       Impact factor: 2.871

5.  Management of allergic rhinitis in the community pharmacy: identifying the reasons behind medication self-selection.

Authors:  Rachel Tan; Biljana Cvetkovski; Vicky Kritikos; Kwok Yan; David Price; Peter Smith; Sinthia Bosnic-Anticevich
Journal:  Pharm Pract (Granada)       Date:  2018-09-26

6.  Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey.

Authors:  Elizabeth A Azzi; Vicky Kritikos; Matthew J Peters; David B Price; Pamela Srour; Biljana Cvetkovski; Sinthia Bosnic-Anticevich
Journal:  BMJ Open       Date:  2019-08-14       Impact factor: 2.692

7.  Prevalence and impact of risk factors for poor asthma outcomes in a large, specialist-managed patient cohort: a real-life study.

Authors:  Gábor Tomisa; Alpár Horváth; Zsuzsanna Szalai; Veronika Müller; Lilla Tamási
Journal:  J Asthma Allergy       Date:  2019-09-23

8.  A multinational observational study identifying primary care patients at risk of overestimation of asthma control.

Authors:  Vicky Kritikos; David Price; Alberto Papi; Antonio Infantino; Bjorn Ställberg; Dermot Ryan; Federico Lavorini; Henry Chrystyn; John Haughney; Karin Lisspers; Kevin Gruffydd-Jones; Miguel Román Rodríguez; Svein Høegh Henrichsen; Thys van der Molen; Victoria Carter; Sinthia Bosnic-Anticevich
Journal:  NPJ Prim Care Respir Med       Date:  2019-12-05       Impact factor: 2.871

9.  Real-life treatment of rhinitis in Australia: a historical cohort study of prescription and over-the-counter therapies for patients with and without additional respiratory disease.

Authors:  David B Price; Pete K Smith; Richard John Harvey; A Simon Carney; Vicky Kritikos; Sinthia Z Bosnic-Anticevich; Louise Christian; Derek Skinner; Victoria Carter; Alice Ms Durieux
Journal:  Pragmat Obs Res       Date:  2018-08-15

10.  High Use of SABAs is Associated with Higher Exacerbation Rate in Dutch Patients with Asthma.

Authors:  Anna Jetske Baron; Bertine M J Flokstra-de Blok; Huib A M Kerstjens; Gineke Koopmans-Klein; David B Price; Andrea A Sellink; Ioanna Tsiligianni; Janwillem W H Kocks
Journal:  J Asthma Allergy       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.